Do children with perinatally acquired HIV infection have problems with metabolism and body shape?

HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007

Michael Dube, for NATAP.org

Kathy Mulligan of UCSF presented data on behalf of a large Paediatric ACTG cohort (127 boys, 113 girls) with prolonged antiretroviral exposures who were compared to HIV-uninfected control children. The children receiving PI tended to have slightly more advanced HIV disease and longer durations of therapy than those on non-PI regimens.

Total fat and limb fat were lower in both PI and no-PI groups but even though BMI was less in the HIV-infected subjects in general, trunk fat was not different in the PI-treated individuals - suggesting that perhaps PIs led to greater trunk fat accumulation in these patients.

Lean body mass was similar to controls in both groups, which meant that the difference in BMI between HIV-infected children and controls was primarily due to loss of (or conversely, failure to gain) body fat. Other than triglycerides being slightly higher in the non-PI subjects, compared to controls lipid values were quite similar. But the PI-treated children had much greater elevations in triglycerides, but unlike the no-PI kids, the PI group also had significantly higher total cholesterol, LDLcholesterol, and non-HDL cholesterol levels and lower HDL cholesterol levels.

There was evidence for increased insulin resistance in both of the HIV-positive groups.

While these data are not as valuable as those from a randomised trial, they do suggest that attention needs to be paid to managing cardiovascular risk factors in children with HIV and perhaps greatest emphasis should be for those with more advanced HIV disease and those receiving PI therapy.

It is not clear however, that PI use should be avoided in these children. Kathy Mulligan emphasised these were preliminary results and they continue to review the data for subsequent reporting.

Ref: Mulligan K et al. Dyslipidemia in vertically infected children and youth on protease inhibitor (PI)-containing antiretroviral therapy (ART): preliminary results of PACTG 1045.

2007-08-10
IB070808-24

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.